Keyword: Seattle Genetics
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.
Clay Siegall's equity awards skyrocketed to $15.8 million last year from $6.8 million in 2017, pushing his total higher than many a CEO's pay.
Last month, Seattle Genetics scored a fast FDA nod for Adcetris in patients with newly diagnosed peripheral T-cell lymphoma, and new data show why.
Seattle Genetics CEO Clay Siegall was impressed by the FDA's first speedy real-time review nods, but his company would soon win an even faster OK.
As Seattle Genetics executives work to grow Adcetris into a blockbuster, the drug picked up its latest FDA nod on Friday.
Seattle Genetics officially has the first-line Adcetris nod in advanced classical Hodgkin lymphoma that it’s been gunning for.
With full data out from a trial of Seattle Genetics’ Adcetris classical Hodgkin lymphoma, at least one analyst is iffy about the drug’s prospects.
Bristol-Myers Squibb is selling a clinical materials manufacturing facility in Washington to Seattle Genetics, which will keep the 72 workers.
Good news for Seattle Genetics and Takeda: Adcetris hit its goal in a Hodgkin lymphoma trial. Not so good? It didn't beat a standard regimen by much.